- Home
- / Iterum Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Iterum Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$1.5
2024-10-29
Market Capitalization
$32.9 M
2024-10-29
CreditSafe Score
?
Score changed on Jun 14, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 869.0K | 37.0K | |||||
| Cost of goods sold | 224.0K | ||||||
| Gross profit | 1.3M | 233.0K | 553.0K | 195.0K | 503.0K | 82.0K | (224.0K) |
| Gross profit margin, % | 629.7% | ||||||
| Operating expense total | 77.3M | 102.0M | 32.1M | 22.4M | 27.8M | 45.7M | 18.2M |
| Depreciation and amortization | 136.0K | 24.0K | 31.0K | 2.1M | 1.8M | 1.8M | 284.0K |
| EBITDA | (76.0M) | (101.8M) | (31.5M) | (22.2M) | (27.3M) | (45.6M) | (18.4M) |
| EBITDA margin, % | -275137.8% | ||||||
| EBIT | (76.2M) | (101.8M) | (31.6M) | (24.3M) | (46.5M) | (47.4M) | (18.7M) |
| EBIT margin, % | -275202.7% | ||||||
| Interest expense | 426.0K | 861.0K | 17.9M | 5.6M | 2.4M | 1.4M | 2.5M |
| Pre tax profit | (76.6M) | (102.7M) | (51.3M) | (90.9M) | (43.4M) | (37.8M) | (24.5M) |
| Income tax expense | 472.0K | 444.0K | 743.0K | 705.0K | 301.0K | 613.0K | 240.0K |
| Net Income | (77.1M) | (103.1M) | (52.0M) | (91.6M) | (43.7M) | (38.4M) | (24.8M) |